

## Areas of Development Interest for External Collaborations

### Immuno-Oncology

#### Cutaneous Squamous Cell Carcinoma (CSCC)

- Neoadjuvant settings combination studies
- Adjuvant use of Cemiplimab in select populations
- Combination studies with Cemiplimab in advanced stages
- Use of Cemiplimab in population already treated for metastatic disease with immuno-therapy

#### Other skin cancers

- Study proposals for skin tumor types (Merkel Cell, Melanoma, Adnexal Tumors, Skin Lymphomas) will be considered and will be evaluated under provision of strong scientific rationale and solid hypothesis of benefit/safety increment over the current treatment landscape

#### Basal Cell carcinoma (BCC)

- Combination studies with Cemiplimab in all treatment stages
- Cemiplimab in surgery or RT eligible patients before other systemic therapies
- Cemiplimab in other pre-BCC genetic syndromes or high-risk populations
- Insights on the biology of disease, genetic risk for progression, Biomarkers

#### Metastatic Non-Small Cell Lung Cancer (mNSCLC)

- Studies in select patient subgroup to address specific medical needs not covered by the current standard of care.
- Studies that can further improve understanding of the disease and inform future directions of specific treatments

#### Other Cancers

- Novel combinations will be considered in HPV+ cancers (e.g., oropharyngeal cancer, HNSCC, anal cancer, and penile cancer)
- Preclinical research on HPV+ cancers responsiveness to IO therapies.
- Studies with Cemiplimab- either as single agent or in combination with other IO agents with available toxicity profile and dynamics data, radiation therapy (no abscopal effect probe), or other biologics.